Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aytu BioScience, Inc is a biotechnology business based in the US. Aytu BioScience shares (AYTU) are listed on the NASDAQ and all prices are listed in US Dollars. Aytu BioScience employs 75 staff and has a trailing 12-month revenue of around USD$51.7 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced investors
52-week range | USD$3.352 - USD$29.9 |
---|---|
50-day moving average | USD$7.9668 |
200-day moving average | USD$9.3796 |
Wall St. target price | USD$20.6 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.481 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$51.7 million |
---|---|
Gross profit TTM | USD$20.1 million |
Return on assets TTM | -10.19% |
Return on equity TTM | -34.38% |
Profit margin | -43.16% |
Book value | $6.302 |
Market capitalisation | USD$140.4 million |
TTM: trailing 12 months
There are currently 340,661 Aytu BioScience shares held short by investors – that's known as Aytu BioScience's "short interest". This figure is 1.8% up from 334,748 last month.
There are a few different ways that this level of interest in shorting Aytu BioScience shares can be evaluated.
Aytu BioScience's "short interest ratio" (SIR) is the quantity of Aytu BioScience shares currently shorted divided by the average quantity of Aytu BioScience shares traded daily (recently around 630853.7037037). Aytu BioScience's SIR currently stands at 0.54. In other words for every 100,000 Aytu BioScience shares traded daily on the market, roughly 540 shares are currently held short.
However Aytu BioScience's short interest can also be evaluated against the total number of Aytu BioScience shares, or, against the total number of tradable Aytu BioScience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aytu BioScience's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aytu BioScience shares in existence, roughly 20 shares are currently held short) or 0.0193% of the tradable shares (for every 100,000 tradable Aytu BioScience shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aytu BioScience.
Find out more about how you can short Aytu BioScience stock.
We're not expecting Aytu BioScience to pay a dividend over the next 12 months.
Aytu BioScience's shares were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu BioScience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Aytu BioScience shares which in turn could have impacted Aytu BioScience's share price.
Over the last 12 months, Aytu BioScience's shares have ranged in value from as little as $3.352 up to $29.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu BioScience's is -0.2545. This would suggest that Aytu BioScience's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu BioScience has bucked the trend.
Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.
Everything we know about the Reddit IPO, plus information on how to buy in.
Everything we know about the Hayward Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Alignment Healthcare Inc IPO, plus information on how to buy in.
Everything we know about the Olink Holding AB (publ) IPO, plus information on how to buy in.
Everything we know about the Procore IPO, plus information on how to buy in.
Everything we know about the Navios South American Logistics Inc IPO, plus information on how to buy in.
Everything we know about the Lava Therapeutics IPO, plus information on how to buy in.
Everything we know about the Pop Culture Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Bukalapak IPO, plus information on how to buy in.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.